"Our number one priority as a company right now is to bring to market a Pan-respiratory annual booster vaccine, which we plan to always customize and upgrade," Chief Executive Officer Stéphane Bancel says
Japan on Thursday suspended the use of 1.63 million doses shipped to 863 vaccination centres nationwide, more than a week after the domestic distributor, Takeda Pharmaceutical, received reports of contaminants in some vials
The United States has now ordered a total of 500 million Moderna vaccine doses to date, with 110 million set for delivery in the fourth quarter and 90 million to be delivered in the first quarter of 2022.
Moderna, which has supplied 217 million doses of its shot to the US government as of Monday.
Moderna said an initial analysis of a study in adolescents aged 12-17 years showed an efficacy rate of 96% for its vaccine.
The company has also been working on a new version that could extend the time the vaccine can be stored in refrigerator temperatures, making it easier to distribute, especially in lower-income countries.
The company and the Biomedical Advanced Research and Development Authority (BARDA) had initially signed a $483 million deal for the vaccine in July last year, which was later increased to about $1 billion.
As of March 31, 2021, the remaining available funding net of revenue earned under the BARDA Contract, prior to the increased payment, was $317 million, Moderna said in a regulatory filing.